FATE and NKTX have other trials ongoing in certain haematological malignancy. Adoptive transfer can induce long-term and durable remissions after a haploidentical stem cell transplantation in R/R AML. In those that are unable to undergo transplantation across seven published studies (over one hundred patients in total), 34% achieved a complete response to NK cell therapy alone. However, it has been demonstrated that the absence of NKGD2 ligand expression on leukemic stem cells determines therapy resistance and immune escape. PARP1 inhibitors can induce expression of NKG2D ligands, so I would like to see certain combo therapies https://www.nature.com/articles/s41586-019-1410-1
Even for CAR-T, intensive debulking chemo could help those with a high tumour burden https://www.frontiersin.org/articles/10.3389/fonc.2021.706087/full
In June, NKTX filed a protocol amendment with the FDA for the ongoing PhI trial of NKX019 to optimise the trial's design as the company prepares for potential dose expansion cohorts. The amended protocol, now in effect, allows for an increased dose of cyclophosphamide, in line with NKX101, and various expansion cohorts evaluating NKX019 in combination with rituximab. Also, three doses of CAR-NKs per cycle, with them currently enrolling a cohort testing 1.5 billion cells per dose.
Recent IPSC News
- Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting • GlobeNewswire Inc. • 05/10/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:35:23 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 11:30:49 AM
- Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 09:13:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 09:13:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 09:13:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/06/2024 08:52:59 PM
- Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit • GlobeNewswire Inc. • 04/23/2024 11:00:00 AM
- Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics • GlobeNewswire Inc. • 04/11/2024 11:00:00 AM
- Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting • GlobeNewswire Inc. • 04/08/2024 08:05:00 PM
- Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors • GlobeNewswire Inc. • 03/25/2024 11:00:00 AM
- Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/19/2024 11:00:00 AM
- Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 03/14/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 11:29:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/07/2024 09:40:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2024 09:19:18 PM
- Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting • GlobeNewswire Inc. • 03/05/2024 11:03:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:10:11 PM
- Form 144/A - Report of proposed sale of securities: [Amend] • Edgar (US Regulatory) • 02/21/2024 06:04:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/16/2024 09:18:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 10:21:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 10:21:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/06/2024 09:25:29 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/05/2024 08:23:09 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM